(ORGO) Organogenesis Holdings - Overview
Stock: Allograft, Matrix, Substitute, Antimicrobial, Scaffold
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 80.4% |
| Relative Tail Risk | -17.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.56 |
| Alpha | -22.17 |
| Character TTM | |
|---|---|
| Beta | 1.974 |
| Beta Downside | 0.955 |
| Drawdowns 3y | |
|---|---|
| Max DD | 57.17% |
| CAGR/Max DD | 0.23 |
Description: ORGO Organogenesis Holdings December 28, 2025
Organogenesis Holdings (NASDAQ: ORGO) is a U.S.-based regenerative-medicine firm that designs, manufactures and sells a portfolio of advanced-wound-care and surgical-sports-medicine products, ranging from placental allografts (Affinity, Novachor) to bioengineered skin substitutes (Apligraf, Dermagraft) and antimicrobial barrier dressings (PuraPly series). The company also markets a biosynthetic matrix (FortiShield) and a porcine-collagen surgical matrix (PuraForce), and it is advancing ReNu, a cryopreserved suspension for knee-osteoarthritis, through a Phase 3 trial.
In its most recent FY 2023 filing, ORGO reported revenue of roughly $210 million, up about 12 % year-over-year, with a gross margin near 71 % and cash and short-term investments of $150 million, giving it a runway of over three years at current burn rates. The wound-care segment contributed ~68 % of total sales, while the emerging orthopedic pipeline (ReNu) represented less than 5 % of revenue but is expected to be a multi-year growth catalyst if Phase 3 confirms efficacy.
Key macro drivers for ORGO include the aging U.S. population and the rising prevalence of chronic wounds (estimated >6 million patients) that are reimbursed largely through Medicare’s wound-care bundles, as well as the broader biotech trend toward biologics and tissue-engineered therapies, which have seen a compound annual growth rate of ~9 % over the past five years.
For deeper quantitative analysis, you might explore ValueRay’s ORGO dashboard.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 1.00m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA -11.00 > 1.0 |
| NWC/Revenue: 45.04% < 20% (prev 35.43%; Δ 9.61% < -1%) |
| CFO/TA -0.08 > 3% & CFO -38.8m > Net Income 1.00m |
| Net Debt (-23.6m) to EBITDA (19.8m): -1.19 < 3 |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (130.8m) vs 12m ago -2.30% < -2% |
| Gross Margin: 74.48% > 18% (prev 0.75%; Δ 7373 % > 0.5%) |
| Asset Turnover: 97.27% > 50% (prev 102.0%; Δ -4.69% > 0%) |
| Interest Coverage Ratio: 0.75 > 6 (EBITDA TTM 19.8m / Interest Expense TTM 2.11m) |
Altman Z'' 2.02
| A: 0.41 (Total Current Assets 299.7m - Total Current Liabilities 90.3m) / Total Assets 509.8m |
| B: -0.09 (Retained Earnings -46.8m / Total Assets 509.8m) |
| C: 0.00 (EBIT TTM 1.57m / Avg Total Assets 478.1m) |
| D: -0.38 (Book Value of Equity -46.8m / Total Liabilities 123.8m) |
| Altman-Z'' Score: 2.02 = BBB |
Beneish M -2.38
| DSRI: 1.63 (Receivables 168.8m/101.3m, Revenue 465.0m/455.0m) |
| GMI: 1.01 (GM 74.48% / 75.29%) |
| AQI: 1.04 (AQ_t 0.19 / AQ_t-1 0.19) |
| SGI: 1.02 (Revenue 465.0m / 455.0m) |
| TATA: 0.08 (NI 1.00m - CFO -38.8m) / TA 509.8m) |
| Beneish M-Score: -2.38 (Cap -4..+1) = BBB |
What is the price of ORGO shares?
Over the past week, the price has changed by -5.75%, over one month by -13.53%, over three months by -3.08% and over the past year by +6.20%.
Is ORGO a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ORGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.5 | 125.5% |
| Analysts Target Price | 8.5 | 125.5% |
| ValueRay Target Price | 3.6 | -4.8% |
ORGO Fundamental Data Overview February 03, 2026
P/S = 1.0912
P/B = 1.9948
Revenue TTM = 465.0m USD
EBIT TTM = 1.57m USD
EBITDA TTM = 19.8m USD
Long Term Debt = 40.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.79m USD (from shortTermDebt, last quarter)
Debt = 40.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.6m USD (from netDebt column, last quarter)
Enterprise Value = 484.1m USD (507.6m + Debt 40.8m - CCE 64.4m)
Interest Coverage Ratio = 0.75 (Ebit TTM 1.57m / Interest Expense TTM 2.11m)
EV/FCF = -9.37x (Enterprise Value 484.1m / FCF TTM -51.7m)
FCF Yield = -10.67% (FCF TTM -51.7m / Enterprise Value 484.1m)
FCF Margin = -11.11% (FCF TTM -51.7m / Revenue TTM 465.0m)
Net Margin = 0.22% (Net Income TTM 1.00m / Revenue TTM 465.0m)
Gross Margin = 74.48% ((Revenue TTM 465.0m - Cost of Revenue TTM 118.7m) / Revenue TTM)
Gross Margin QoQ = 75.97% (prev 72.58%)
Tobins Q-Ratio = 0.95 (Enterprise Value 484.1m / Total Assets 509.8m)
Interest Expense / Debt = 1.02% (Interest Expense 415.0k / Debt 40.8m)
Taxrate = 1.85% (407.0k / 22.0m)
NOPAT = 1.54m (EBIT 1.57m * (1 - 1.85%))
Current Ratio = 3.32 (Total Current Assets 299.7m / Total Current Liabilities 90.3m)
Debt / Equity = 0.11 (Debt 40.8m / totalStockholderEquity, last quarter 386.0m)
Debt / EBITDA = -1.19 (Net Debt -23.6m / EBITDA 19.8m)
Debt / FCF = 0.46 (negative FCF - burning cash) (Net Debt -23.6m / FCF TTM -51.7m)
Total Stockholder Equity = 375.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.21% (Net Income 1.00m / Total Assets 509.8m)
RoE = 0.27% (Net Income TTM 1.00m / Total Stockholder Equity 375.1m)
RoCE = 0.38% (EBIT 1.57m / Capital Employed (Equity 375.1m + L.T.Debt 40.8m))
RoIC = 0.62% (NOPAT 1.54m / Invested Capital 248.5m)
WACC = 12.28% (E(507.6m)/V(548.5m) * Re(13.19%) + D(40.8m)/V(548.5m) * Rd(1.02%) * (1-Tc(0.02)))
Discount Rate = 13.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
Fair Price DCF = unknown (Cash Flow -51.7m)
EPS Correlation: -20.34 | EPS CAGR: -1.35% | SUE: -2.90 | # QB: 0
Revenue Correlation: 1.92 | Revenue CAGR: 4.36% | SUE: 1.94 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.17 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-22.7% | Growth Revenue=+6.3%